Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-22T18:11:39.438Z Has data issue: false hasContentIssue false
  • English
  • Français

CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy

Published online by Cambridge University Press:  16 April 2020

Georg Nikisch  and
Aleksander A. Mathé
Georg Nikisch*
Affiliation:
Department of Psychiatry and Psychotherapy, Klinikum Fulda gAG, Pacelliallee 4, D-36043Fulda, Germany
Aleksander A. Mathé
Affiliation:
Department of Clinical Neuroscience, Division of Psychiatry, Karolinska Institutet, Karolinska University Hospital, Huddinge SE-141 86Stockholm, Sweden
*
*Corresponding author. Tel.: +49 661 84 5736; fax: +49 661 84 5722. E-mail address: [email protected] (G. Nikisch).
Get access

Abstract

Antidepressant drugs affect monoamines and neuropeptides in human cerebrospinal fluid (CSF) and in rodent brain. The purpose of this study was to investigate if also electroconvulsive therapy (ECT) affects these compounds in a similar manner in the CSF of depressed patients. Homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and corticotropin-releasing hormone (CRH)-like immunoreactivity (-LI) and neuropeptide Y (NPY)-LI were determined in CSF in six drug resistant patients with major depression. Lumbar puncture was performed at baseline and after completion of eight ECTs. ECT was associated with an increase in NPY-LI (p = 0.009) and a decrease in CRH-LI (p ≤ 0.001). HVA (p = 0.003) and 5-HIAA (p = 0.002) were significantly increased after the ECT. Findings of NPY increase and CRH decrease were similar to those following chronic treatment with citalopram, indicating that these changes might constitute one of the common underpinnings of antidepressant treatment modalities.

Keywords

Monoamine metabolitesNeuropeptidesECTMajor depressionCSF
Type
Short communication
Information
European Psychiatry , Volume 23 , Issue 5 , August 2008 , pp. 356 - 359
Copyright
Copyright © Elsevier Masson SAS 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ågren, H.Metford, I.N.Rudorfer, M.V.Linnoila, M.Potter, W.Z.Interacting neurotransmitter systems. A non-experimental approach to the 5-HIAA-HVA correlation in human CSF J Psychiatr Res 20 1986 175–193.Google Scholar
Åsberg, M.Bertilsson, L.Mártensson, B.Scalia-Tomba, G.P.Thorén, P.Träskman-Bentz, L.CSF monoamine metabolites in melancholia Acta Psychiatr Scand 69 1984 201–219.Google Scholar
Bauer, M.Whybrow, P.C.Angst, J.Versiani, M.Moller, H.J.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder World J Biol Psychiatry 1 2002 5–43.Google Scholar
Bauer, M.Whybrow, P.C.Angst, J.Versiani, M.Moller, H.J.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions World J Biol Psychiatry 2 2002 69–86.CrossRefGoogle Scholar
Bjornebekk, A.Mathé, A.A.Brene, S.Running has differential effects on NPY, opiates, and cell proliferation in an animal model of depression and controls Neuropsychopharmacology 31 2006 256–264.Google Scholar
Britton, K.T.Akwa, Y.Spina, M.G.Koob, G.F.Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze Peptides 21 2000 37–44.Google Scholar
Caberlotto, L.Hurd, Y.L.Neuropeptide Y Y(1) and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior Neuropsychopharmacology 25 1 2001 91–97.Google Scholar
Caberlotto, L.Jimenez, P.Overstreet, D.H.Hurd, Y.L.Mathé, A.A.Fuxe, K.Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression Neurosci Lett 265 3 1999 191–194.Google Scholar
De Bellis, M.D.Gold, P.W.Geracioti, T.D.Listwak, S.J.Kling, M.A.Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression Am J Psychiatry 158 1993 656–657.Google Scholar
Ehlers, C.L.Somes, C.Seifritz, E.Rivier, J.E.CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety Depress Anxiety 6 1997 1–9.Google ScholarPubMed
Fava, G.A.Ruini, C.Sonino, N.Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach CNS Drugs 17 2003 1109–1117.Google Scholar
Heilig, M.Zachrisson, O.Thorsell, A.Ehnvall, A.Mottagui-Tabar, S.Sjogren, M. et al Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism J Psychiatr Res 38 2004 113–121.Google Scholar
Husum, H.Gruber, S.H.Bolwig, T.G.Mathé, A.A.Extracellular levels of NPY in the dorsal hippocampus of freely moving rats are markedly elevated following a single electroconvulsive stimulation, irrespective of anticonvulsive Y1 receptor blockade Neuropeptides 36 5 2002 363–369.Google Scholar
Husum, H.Mathé, A.A.Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes Neuropsychopharmacology 27 5 2002 756–764.Google Scholar
Husum, H.Mikkelsen, J.D.Hogg, S.Mathé, A.A.Mork, A.Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram Neuropharmacology 39 8 2000 1463–1473.Google Scholar
Husum, H.Vasquez, P.A.Mathé, A.A.Changed concentrations of tachykinins and neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram Neuropsychopharmacology 24 2 2001 183–191.Google Scholar
Jimenez-Vasquez, P.A.Diaz-Cabiale, Z.Caberlotto, L.Bellido, I.Overstreet, D.Fuxe, K. et al Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression Eur Neuropsychopharmacol 17 2007 298–308.Google Scholar
Jimenez-Vasquez, P.A.Overstreet, D.H.Mathé, A.A.Neuropeptide Y in male and female brains of Flinders Sensitive Line, a rat model of depression. Effects of electroconvulsive stimuli J Psychiatr Res 34 2000 405–412.Google Scholar
Jimenez-Vasquez, P.A.Salmi, P.Ahlenius, S.Mathé, A.A.Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion Behav Brain Res 111 2000 115–123.Google Scholar
Kask, A.Harro, J.von Horsten, S.Redrobe, J.P.Dumont, Y.Quirion, R.The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y Neurosci Biobehav Rev 26 2002 259–283.Google Scholar
Little, J.T.Ketter, T.A.Mathé, A.A.Frye, M.A.Luckenbaugh, D.Post, R.M.Venlafaxine but not buproprion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression Biol Psychiatry 45 1999 285–289.Google ScholarPubMed
Mathé, A.A.Neuropeptides and electroconvulsive treatment J ECT 15 1999 1–15.Google Scholar
Mathé, A.A.Gruber, S.H.M.Neuropeptide Y has marked antidepressant properties in a rat model of depression Neuropsychopharmacology 29 Suppl. 1 2004 S154.Google Scholar
Mathé, A.A.Rudorfer, M.V.Stenfors, C.Manji, H.K.Potter, W.Z.Theodorsson, E.Effects of electroconvulsive treatment on somatostatin, neuropeptide Y, endothelin, and neurokinin A concentrations in cerebrospinal fluid of depressed patients: a pilot study Depression 3 1996 250–256.Google Scholar
Mathé, A.A.Stenfors, C.Brodin, E.Theodorsson, E.Neuropeptides in brain: effects of microwave irradiation and decapitation Life Sci 46 1990 287–293.Google Scholar
Muller, M.Holsboer, F.Keck, M.E.Genetic modification of corticosteroid receptor signaling: novel insights into pathophysiology and treatment strategies of human affective disorders Neuropeptides 36 2002 117–131.Google Scholar
Muller, M.Uhr, M.Holsboer, F.Keck, M.E.Hypothalamic-pituitary-adrenocortical system and mood disorders: highlights from mutant mice Neuroendocrinology 79 2004 1–12.Google Scholar
Nemeroff, C.B.Bissette, G.Akil, H.Fink, M.Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotropin-releasing factor, beta-endorphin and somatostatin Br J Psychiatry 158 1991 59–63.Google Scholar
Nikisch, G.Agren, H.Eap, C.B.Czernik, A.Baumann, P.Mathé, A.A.Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram Int J Neuropsychopharmacol 8 2005 403–410.Google Scholar
Nikisch, G.Mathé, A.A.Czernik, A.Eap, C.B.Jimenez-Vasquez, P.Brawand-Amey, M. et al Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response J Clin Psychopharmacol 24 3 2004 283–290.Google Scholar
Nilsson, C.Karlsson, G.Blennow, K.Heilig, M.Ekmann, R.Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients Peptides 17 3 1996 359–362.Google Scholar
Redrobe, J.P.Dumont, Y.Fournier, A.Quirion, R.The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test Neuropsychopharmacology 26 2002 615–624.Google Scholar
Rudorfer, M.V.Risby, E.D.Osman, O.T.Gold, P.W.Potter, W.Z.Hypothalamic–pituitary–adrenal axis and monoamine transmitter activity in depression: a pilot study of central and peripheral effects of electroconvulsive therapy Biol Psychiatry 29 1991 253–264.Google Scholar
Stenfors, C.Mathé, A.A.Theodorsson, E.Repeated electroconvulsive stimuli: changes in neuropeptide Y, neurotensin and tachykinin concentrations in time Prog Neuro-psychopharmacol Biol Psychiatry 18 1994 201–209.Google Scholar
Stenfors, C.Theodorsson, E.Mathé, A.A.Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain J Neurosci Res 24 1989 445–450.Google Scholar
Strohle, A.Holsboer, F.Stress responsive neurohormones in depression and anxiety Pharmacopsychiatry 36 2003 207–214.Google Scholar
Vezzani, A.Ravizza, T.Moneta, D.Conti, M.Rizzi, M.Samanin, R. et al Brain-derived neurotrophic factor immunoreactivity in the limbic system of rats after acute seizures and during spontaneous convulsions: temporal evolution of changes as compared to neuropeptide Y Neuroscience 90 4 1999 1445–1461.Google Scholar
Wahlestedt, C.Pich, E.M.Koob, G.F.Yee, F.Heilig, M.Modulation of anxiety and neuropeptide Y-Y1 by antisense oligodeoxynucleotides Science 259 1993 528–531.Google Scholar
Westrin, A.Ekman, R.Träskman-Bendz, L.Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt Eur Neuropsychopharmacol 9 3 1999 205–211.Google Scholar
Zachrisson, O.Mathé, A.A.Stenfors, C.Lindefors, N.Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA expression in the rat brain Molec Brain Res 31 1995 71–85.Google Scholar
Submit a response

Comments

No Comments have been published for this article.